Osiris Therapeutics (OSIR) researches, develops, manufactures, markets, and distributes regenerative medicine products.
OSIR products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.
Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
September 11, 2013
The second time this month that the FDA has raised HCT/P questions
September 6, 2013
MiMedx (MDXG) versus Osiris (OSIR), some stating or seeking comparisons
September 6, 2013
Osiris (OSIR), Grafix® Diabetic Foot Ulcer trial results define “closure achievement” supporting “claims”
August 13, 2013
Osiris Therapeutics (OSIR) Jumps +109.57% or +$11.68 to $22.34
August 5, 2013
Osiris Therapeutics (OSIR), Q2/13 results – net loss narrow’s – SELL until it settles
July 23, 2013
NeoStem (NYSE MKT: NBS) moves trading to NASDAQ
July 21, 2013
NeoStem (NYSE MKT: NBS) Stephen Potter's appointed as EVP
July 16, 2013
Osiris Q2 Conference Call
May 7, 2013
Osiris (OSIR) released its results for Q1 2013
March 7, 2013
Osiris (OSIR) Q4/12 and FY12 Results
35 companies, 1 interpreter!
Insight, foresight and recommendation
Osiris Therapeutics (OSIR) – Late Filing, SEC issues, officer crimminal indictments and yet another COO departs (number 5 in four years?). Started the year 2018 at $6.15, dived and jived to $6.95 by 2/1 and achieved $9.08 by 2/21. Once their "clean" it will be worth a near term topic until then "play" monopoly with the shares ... NO trust
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.